Vaccine production gradually ramped up, says Centre
Updated:
Updated:
The vaccine production was expected to increase in the next couple of months, it stated
Share Article
The vaccine production was expected to increase in the next couple of months, it stated
The Centre informed the Supreme Court that the production capacity of COVID-19 vaccines had been “gradually ramped up” in the light of the immunisation drive.
“In times of grave and unprecedented crisis when the nation is fighting a disaster of unprecedented magnitude, the executive functioning of the government needs discretion to formulate policy in larger interest. It is submitted that in view of the unprecedented and peculiar circumstances under which vaccination drive is devised as an executive policy, the wisdom of the executive should be trusted,” it noted.
The Centre has informed the Supreme Court that no governmental aid, assistance or grant was made either for research or development of COVID-19 vaccines - Covaxin and Covishield - but some financial assistance was given for conducting clinical trials. In an affidavit filed in the apex court on Sunday night, the Centre has said that Covaxin has been developed under public private partnership between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL). ICMR has not provided any funds to BBIL for Covaxin development. However, funds have been spent in various activities undertaken by ICMR-NIV, Pune for Covaxin development. Also phase 3 clinical trials of Covaxin have been funded by ICMR. The trials have been conducted at 22 sites in 25,800 participants, the affidavit said, adding that total estimated expenditure of ICMR in this was 35 crore.
NEW DELHI: The Centre has informed the Supreme Court that no governmental aid, assistance or grant was made either for research or development of Covid-19 vaccines - Covaxin and Covishield - but some financial assistance was given for conducting clinical trials.
In an affidavit filed in the apex court on Sunday night, the Centre has said that Covaxin has been developed under public private partnership between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL).
“ICMR has not provided any funds to BBIL for Covaxin development. However, funds have been spent in various activities undertaken by ICMR-NIV, Pune for Covaxin development. Also phase 3 clinical trials of Covaxin have been funded by ICMR. The trials have been conducted at 22 sites in 25,800 participants,” the affidavit said, adding that total estimated expenditure of ICMR in this was 35 crore.
Gave some financial aid for Covaxin, Covishield trials, not R&D: Govt
By IANS |
Published on
Mon, May 10 2021 22:27 IST |
7 Views
Bharat Biotech gets permission to manufacture Covaxin for sale (Lead, correcting para 1) . Image Source: IANS News
New Delhi, May 10 : The Centre has told the Supreme Court that no governmental aid, assistance or grant was made either for research or development of either Covaxin or Covishield vaccines but some financial assistance was given for conducting clinical trials.
In an affidavit, the Centre said that Covaxin has been developed under public private partnership (PPP) between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL). The PPP was executed under a formal MoU between the ICMR and the BBIL which includes a 5 per cent royalty clause for the ICMR on net sales and other clauses like prioritisation of in-country supplies, and the product intellectual property rights are shared
Production capacity of Covid vaccines ‘gradually ramped-up’: Govt tells SC
May 10, 2021
×
The Centre has informed the Supreme Court that the production capacity of Covid-19 vaccines has been “gradually ramped-up” in light of the immunisation drive.
“In times of grave and unprecedented crisis when the nation is fighting a disaster of unprecedented magnitude, the executive functioning of the government needs discretion to formulate policy in larger interest. It is submitted that in view of the unprecedented and peculiar circumstances under which vaccination drive is devised as an executive policy, the wisdom of the executive should be trusted,” the Centre noted.
SII, Bharat Biotech